Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease

Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals. Methods: Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA. Results: Median age of the cohort was 45 years (41–51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42–9.19) vs. 2.42 ng/mL (95% CI = 1.73–5.95), p = 0.033; 9.5 ng/mL (95% CI = 7.7–13.6) vs. 6.2 ng/mL (95% CI = 4.9–8.9), p = 0.016; 6.6 ng/mL (95% CI = 5.6–7.9) vs. 5.1 ng/mL (95% CI = 4.2–5.4), p = 0.013, respectively). Irisin levels were similarly distributed between the features of NASH. Circulating irisin positively correlated with both PRO-C3 and PRO-C6 levels (r = 0.47, p = 0.008 and r = 0.46, p = 0.002). Conclusions: Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage.

[1]  E. Bugianesi,et al.  Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease , 2021, Metabolites.

[2]  Fang-Xiong Wu,et al.  Circulating Irisin Levels in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis , 2020, Gastroenterology research and practice.

[3]  Xiaoshuang Zhou,et al.  Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study , 2020, Scientific Reports.

[4]  Anastasios Koulaouzidis,et al.  Irisin in Liver Cirrhosis , 2020, Journal of clinical medicine.

[5]  M. Karsdal,et al.  Collagen Formation Assessed by N‐Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography , 2019, Hepatology.

[6]  M. Karsdal,et al.  Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes , 2019, Diabetes Care.

[7]  T. Berg,et al.  A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. , 2019, Journal of hepatology.

[8]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[9]  Kyu-Sang Park,et al.  Circulating irisin levels as a predictive biomarker for sarcopenia: A cross‐sectional community‐based study , 2017, Geriatrics & gerontology international.

[10]  G. Svegliati-Baroni,et al.  Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease , 2017, The Journal of clinical endocrinology and metabolism.

[11]  J. Steinacker,et al.  Association between circulating irisin and insulin resistance in non-diabetic adults: A meta-analysis. , 2016, Metabolism: clinical and experimental.

[12]  M. Zou,et al.  Irisin Is Regulated by CAR in Liver and Is a Mediator of Hepatic Glucose and Lipid Metabolism. , 2016, Molecular endocrinology.

[13]  Weizhen Zhang,et al.  Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling , 2016, EBioMedicine.

[14]  Hai-Jian Sun,et al.  Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. , 2015, Clinical science.

[15]  J. Moreno-Navarrete,et al.  Circulating Irisin Levels Are Positively Associated with Metabolic Risk Factors in Sedentary Subjects , 2015, PloS one.

[16]  Ting Gao,et al.  Circulating levels of irisin in middle-aged first-degree relatives of type 2 diabetes mellitus — correlation with pancreatic β-cell function , 2014, Diabetology & Metabolic Syndrome.

[17]  C. Mantzoros,et al.  The effect of Irisin on antioxidant system in liver. , 2014, Free radical biology & medicine.

[18]  P. Vokonas,et al.  Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events , 2014, International Journal of Obesity.

[19]  Sungeun Kim,et al.  Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. , 2014, The Journal of clinical endocrinology and metabolism.

[20]  C. Mantzoros,et al.  Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans , 2014, International Journal of Obesity.

[21]  D. Gašperíková,et al.  Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies , 2014, The Journal of physiology.

[22]  Zheng Chen,et al.  Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. , 2013, Journal of hepatology.

[23]  J. Moreno-Navarrete,et al.  Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. , 2013, The Journal of clinical endocrinology and metabolism.

[24]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[25]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[26]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.